What is HC Wainwright's Forecast for ANIX Q1 Earnings?

Anixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Anixa Biosciences in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.10) per share for the quarter. HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Anixa Biosciences' current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Anixa Biosciences' Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.40) EPS.

Other research analysts have also issued reports about the company. Maxim Group assumed coverage on Anixa Biosciences in a research report on Friday, March 21st. They set a "buy" rating and a $10.00 target price on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Wednesday.

Anixa Biosciences Price Performance

Shares of NASDAQ:ANIX traded down $0.11 during trading on Wednesday, reaching $2.97. 81,233 shares of the company were exchanged, compared to its average volume of 97,441. Anixa Biosciences has a 12-month low of $2.07 and a 12-month high of $4.20. The business's fifty day simple moving average is $2.97 and its 200-day simple moving average is $3.00. The firm has a market capitalization of $95.63 million, a PE ratio of -7.62 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10).

Institutional Trading of Anixa Biosciences

Several institutional investors have recently made changes to their positions in ANIX. Millennium Management LLC bought a new stake in shares of Anixa Biosciences during the fourth quarter worth $26,000. Virtu Financial LLC acquired a new position in Anixa Biosciences during the third quarter valued at approximately $34,000. Renaissance Technologies LLC raised its position in shares of Anixa Biosciences by 36.5% in the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after purchasing an additional 3,900 shares during the period. Prosperity Wealth Management Inc. bought a new stake in shares of Anixa Biosciences during the fourth quarter worth approximately $54,000. Finally, Jane Street Group LLC bought a new position in Anixa Biosciences during the 4th quarter worth $67,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Anixa Biosciences

In related news, CEO Amit Kumar purchased 43,000 shares of the company's stock in a transaction on Wednesday, January 15th. The shares were bought at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the transaction, the chief executive officer now owns 559,925 shares of the company's stock, valued at $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of the business's stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of $2.57 per share, with a total value of $25,700.00. Following the completion of the purchase, the director now owns 922,334 shares of the company's stock, valued at approximately $2,370,398.38. The trade was a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 75,289 shares of company stock worth $177,021. 25.30% of the stock is currently owned by company insiders.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.